Huma Therapeutics

Huma Therapeutics is a London-headquartered healthcare AI company that develops a modular, disease-agnostic cloud platform for regulated healthcare, life sciences and government use. Founded in 2011 as Medopad and rebranded to Huma in April 2020, the company originally focused on mobile patient-monitoring software that integrated data from wearables and medical devices for hospitals, particularly in chronic and rare disease management, and later broadened its scope to prevention and general wellbeing.

The core product is the Huma Cloud Platform (HCP), launched alongside the company's Series D in July 2024. It offers no-code configuration of regulated disease-management tools for any therapeutic area, a library of pre-built modules, device connectivity, cloud-agnostic hosting, APIs, hosting and deployment of diagnostic and predictive AI/ML models, an SDK, and a marketplace. Applications built on the platform span remote patient monitoring, patient engagement, virtual care, ambient AI and clinical documentation (Huma Intelligence Scribe), digital triage (A&E eTriage), respiratory monitoring, diabetes in pregnancy (GDm Health), myasthenia gravis, primary care (Huma myGP, via the iPLATO Healthcare primary care division), and decentralised clinical trials with pre-built eConsent, ePRO and eCOA modules.

The company positions the platform as an "operating system" for AI in regulated industries, unifying clinical, operational, research and enterprise data with embedded governance, security, interoperability and regulatory controls, supported by forward-deployment engineers and an internal regulatory function that converts customer-specific builds into cleared products.

Founding story

Dan Vahdat founded the company in 2011 in London as Medopad, alongside co-founder Rich Khatib, to build an enterprise platform connecting patients, healthcare providers and pharmaceutical firms through AI-enabled data pooling and remote monitoring. The 2020 rebrand to Huma reflected a shift from disease-specific monitoring toward prevention and broader physical and mental wellbeing, with the name described as deriving from a term meaning "for all of humanity".

Business model

Huma licenses its cloud platform and regulated applications to health systems, pharmaceutical companies, CROs and governments, and also makes the platform available to third parties with an SDK so they can build or embed their own regulated digital health applications. It owns and operates a portfolio of digital health applications and expands that portfolio through acquisitions, supported by a partnership with growth equity firm Eckuity Capital.

Enterprise sales of platform and application deployments to health systems, pharma, CROs and governments, complemented by US remote patient monitoring reimbursement codes covering contracted lives. Some pandemic-era government deployments were provided on a not-for-profit or pro bono basis.

Traction

Deployments reported across more than 3,000 hospitals and clinics (over 4,500 by 2025), 70+ countries, and engagement with tens of millions of individuals; 800+ research studies supporting roughly 1 million participants; a US respiratory RPM product covering 140,000 contracted lives in 2024, with roughly 500,000 contracted lives across respiratory programmes after the Aluna acquisition. The company reported doubling revenue year-on-year in 2024 and targeting profitability that year.

Latest developments

In May 2025 Huma announced a global partnership and investment agreement with Eckuity Capital to fund an acquisition-led growth strategy, and simultaneously acquired Aluna (Knox Medical Diagnostics, Inc.), a San Francisco-based respiratory remote monitoring and spirometer company, whose products are to be relaunched on the Huma Cloud Platform at FDA Class II classification. The company currently markets the platform as an operating system for AI in regulated industries, with tools including Huma Workspace and Huma Intelligence.